IN2014DN07283A - - Google Patents
Info
- Publication number
- IN2014DN07283A IN2014DN07283A IN7283DEN2014A IN2014DN07283A IN 2014DN07283 A IN2014DN07283 A IN 2014DN07283A IN 7283DEN2014 A IN7283DEN2014 A IN 7283DEN2014A IN 2014DN07283 A IN2014DN07283 A IN 2014DN07283A
- Authority
- IN
- India
- Prior art keywords
- group
- alkyl group
- substituent
- cancer agent
- hydrogen atom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Provided are: a novel compound having an excellent Aurora A selective inhibitory activity and useful as an anti cancer agent that can be administered orally; a novel anti tumor effect enhancer for a microtube agonist comprising a taxane type anti cancer agent; and a combination therapy. A piperidine compound represented by general formula (I) (wherein R represents a carboxyl group C(=O)NRR or an oxadiazolyl group which may have a C C alkyl group or a trifluoromethyl group as a substituent; R represents a halogen atom or a C C alkoxy group; R represents a phenyl group which may have 1 to 3 groups independently selected from a halogen atom a C C alkyl group a C C alkoxy group and a trifluoromethyl group as a substituent or substituents; R represents a hydrogen atom or a C C alkyl group; and R and R may be the same as or different from each other and independently represent a hydrogen atom a C C alkyl group or a C C cycloalkyl group or R R and a nitrogen atom to which R and R are bound may together form a 3 to 6 membered nitrogenated saturated heterocyclic group) or a salt thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012043303 | 2012-02-29 | ||
| JP2012186534 | 2012-08-27 | ||
| PCT/JP2013/055064 WO2013129443A1 (en) | 2012-02-29 | 2013-02-27 | Novel piperidine compound or salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07283A true IN2014DN07283A (en) | 2015-04-24 |
Family
ID=49082638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7283DEN2014 IN2014DN07283A (en) | 2012-02-29 | 2013-02-27 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9346787B2 (en) |
| EP (1) | EP2821406B1 (en) |
| JP (1) | JP5323289B1 (en) |
| KR (1) | KR101677823B1 (en) |
| CN (1) | CN104159893B (en) |
| AU (1) | AU2013227024B2 (en) |
| BR (1) | BR112014021519B1 (en) |
| CA (1) | CA2865875C (en) |
| DK (1) | DK2821406T3 (en) |
| ES (1) | ES2576497T3 (en) |
| HK (1) | HK1199730A1 (en) |
| HU (1) | HUE028495T2 (en) |
| IN (1) | IN2014DN07283A (en) |
| MX (1) | MX344276B (en) |
| MY (1) | MY169179A (en) |
| PL (1) | PL2821406T3 (en) |
| PT (1) | PT2821406T (en) |
| RU (1) | RU2581834C1 (en) |
| SG (1) | SG11201405318PA (en) |
| TW (1) | TWI485146B (en) |
| WO (1) | WO2013129443A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI485146B (en) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| US9012475B2 (en) | 2013-08-27 | 2015-04-21 | Taiho Pharmaceutical Co., Ltd. | Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor |
| KR101430209B1 (en) * | 2014-03-06 | 2014-08-14 | 강원대학교산학협력단 | Diagnostic method for measuring protein kinase activity and diagnostic kit therefor |
| TWI693218B (en) | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | Aurora a kinase inhibitor |
| CN104758286B (en) * | 2015-03-05 | 2016-09-14 | 南京工业大学 | 1-benzyl-4-(2,4 dichloro benzene ethylamino-) piperidines application in preparing antitumor drug |
| US11028069B2 (en) | 2016-12-22 | 2021-06-08 | Taiho Pharmaceutical Co., Ltd. | Salt of substituted piperidine compound |
| US20210236475A1 (en) | 2018-05-29 | 2021-08-05 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and method for tumor therapy |
| CN112239465A (en) * | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | Aurora kinase inhibitor and use thereof |
| CN112898292A (en) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | Novel aurora kinase inhibitor and use thereof |
| TWI785474B (en) * | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | Novel heterocyclic compounds useful as selective aurora a inhibitors |
| AR126581A1 (en) * | 2021-07-28 | 2023-10-25 | Jacobio Pharmaceuticals Co Ltd | POLYMORPHIC FORMS OF SELECTIVE AURORA A INHIBITORS AND USES THEREOF |
| WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
| WO2024088192A1 (en) * | 2022-10-26 | 2024-05-02 | Js Innopharm (Suzhou) Ltd. | An aurora a inhibitor for use in treatments of cancers |
| WO2024088193A1 (en) * | 2022-10-26 | 2024-05-02 | Js Innopharm (Suzhou) Ltd. | Combination of aurora a and parp inhibitors for treatment of cancers |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| SE0302486D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| KR20070072562A (en) * | 2004-10-29 | 2007-07-04 | 반유 세이야꾸 가부시끼가이샤 | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| WO2007022384A2 (en) | 2005-08-18 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
| WO2007024843A2 (en) | 2005-08-26 | 2007-03-01 | Smithkline Beecham Corporation | Pyrimidinyl-pyrazole inhibitors of aurora kinases |
| US7563787B2 (en) * | 2005-09-30 | 2009-07-21 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| JP2009530330A (en) * | 2006-03-20 | 2009-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | Phthalazinone pyrazole derivatives, their production and use as pharmaceuticals |
| WO2007107469A1 (en) | 2006-03-20 | 2007-09-27 | F. Hoffmann-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
| JP2008081492A (en) * | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | New aminopyridine derivative having aurora a selective inhibitory action |
| GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
| EP2170065A4 (en) | 2007-06-20 | 2011-11-23 | Merck Sharp & Dohme | Diphenyl substituted alkanes |
| AU2009216062B2 (en) * | 2008-02-22 | 2013-02-07 | Msd K.K. | Novel aminopyridine derivatives having Aurora A selective inhibitory action |
| CN102548558B (en) * | 2009-03-23 | 2014-04-30 | Msdk.K.公司 | Novel aminopyridine derivatives having Aurora A selective inhibitory action |
| WO2010111056A1 (en) * | 2009-03-24 | 2010-09-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| TWI485146B (en) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
-
2013
- 2013-02-26 TW TW102106767A patent/TWI485146B/en active
- 2013-02-27 SG SG11201405318PA patent/SG11201405318PA/en unknown
- 2013-02-27 WO PCT/JP2013/055064 patent/WO2013129443A1/en active Application Filing
- 2013-02-27 KR KR1020147023717A patent/KR101677823B1/en active IP Right Grant
- 2013-02-27 CA CA2865875A patent/CA2865875C/en active Active
- 2013-02-27 ES ES13755229.5T patent/ES2576497T3/en active Active
- 2013-02-27 CN CN201380011842.0A patent/CN104159893B/en active Active
- 2013-02-27 MY MYPI2014702424A patent/MY169179A/en unknown
- 2013-02-27 HU HUE13755229A patent/HUE028495T2/en unknown
- 2013-02-27 IN IN7283DEN2014 patent/IN2014DN07283A/en unknown
- 2013-02-27 JP JP2013523421A patent/JP5323289B1/en active Active
- 2013-02-27 RU RU2014138987/04A patent/RU2581834C1/en active
- 2013-02-27 AU AU2013227024A patent/AU2013227024B2/en active Active
- 2013-02-27 PT PT137552295T patent/PT2821406T/en unknown
- 2013-02-27 EP EP13755229.5A patent/EP2821406B1/en active Active
- 2013-02-27 BR BR112014021519-7A patent/BR112014021519B1/en active IP Right Grant
- 2013-02-27 PL PL13755229.5T patent/PL2821406T3/en unknown
- 2013-02-27 US US14/381,814 patent/US9346787B2/en active Active
- 2013-02-27 DK DK13755229.5T patent/DK2821406T3/en active
- 2013-02-27 MX MX2014010395A patent/MX344276B/en active IP Right Grant
-
2015
- 2015-01-07 HK HK15100157.2A patent/HK1199730A1/en unknown
-
2016
- 2016-04-18 US US15/131,372 patent/US10092556B2/en active Active
-
2018
- 2018-08-31 US US16/118,912 patent/US20180369224A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07283A (en) | ||
| PH12018502633A1 (en) | Substituted pyridines as inhibitors of dnmt1 | |
| PH12014501719A1 (en) | Pyridone derivatives | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| CA2875877C (en) | Syk inhibitors | |
| NZ715747A (en) | Syk inhibitors | |
| MX2014011829A (en) | N-substituted pyridinylidene compounds and derivatives for combating animal pests. | |
| EA201690752A1 (en) | INHIBITORS G12C KRAS | |
| MX2013004407A (en) | Pyridine derivative and medicinal agent. | |
| EA201591753A1 (en) | 3-PYRIMIDIN-4-ILOXAZOLIDIN-2-ONE AS MUTANT IDH INHIBITORS | |
| TN2012000608A1 (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| MA34064B1 (en) | HETEROCYCLIC COMPOUND | |
| EP2613782A4 (en) | Indazole derivatives useful as erk inhibitors | |
| MX2013011551A (en) | N-substituted hetero-bicyclic compounds and derivatives for combating animal pests. | |
| EA201391629A1 (en) | CSF-1R INHIBITORS FOR THE TREATMENT OF BRAIN TUMORS | |
| RS52964B (en) | 7-piperidinoalkyl-3,4-dihydroquinolone derivative | |
| IN2014DN07509A (en) | ||
| JO3509B1 (en) | P2x7 modulators | |
| EA201391558A1 (en) | TETRAHYDROPYRAZOLO [1,5-A] Pyrimidine as an anti-tuberculosis compound | |
| EA200900631A1 (en) | SUBSTITUTED PYRAZOLES AND TRIAZOLES AS KIBB INHIBITORS (KYNESIN-PROTEIN VERETEN) | |
| WO2014102592A3 (en) | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof | |
| EP2585446A4 (en) | Compounds having trpv1 antagonistic activity and uses thereof | |
| MX341341B (en) | Benzamide derivatives and their use as hsp90 inhibtors. | |
| MX2013007937A (en) | Novel indole or indazole derivative or salt thereof. | |
| MX2015007116A (en) | New substituted 1,4-dithiine derivatives and their use as fungicides. |